We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ALHC Stock Worth Buying After a Big Rally and Higher Forecasts
Read MoreHide Full Article
Key Takeaways
ALHC's revenues rose 33.3% in Q1 2026 as membership and per-member revenue increased.
Alignment raised 2026 guidance, with EBITDA expected at $138M-$163M amid operating leverage.
ALHC's rally and 0.9X forward sales multiple make valuation a tougher hurdle for new buyers.
Alignment Healthcare (ALHC - Free Report) has given investors a clearer profitability story, but the stock’s rally has made the buy case less straightforward.
The question now is not whether execution has improved. It has. The harder question is whether the current price still leaves enough room for upside after investors have already rewarded that progress.
ALHC Earnings Momentum Looks Real
First-quarter 2026 results showed that Alignment’s operating model is moving beyond a long-range profitability promise. Revenues rose 33.3% year over year to $1.23 billion, supported by membership expansion and higher per-member revenue.
The company reported earnings of 5 cents per share compared with a loss of 5 cents a year earlier. Adjusted EBITDA increased 87.6% to $37.9 million, while the Medical Benefit Ratio improved to 88.2% from 88.4%, signaling modestly better medical-cost control.
Membership reached about 284,800, up 30.9% year over year. Molina Healthcare (MOH - Free Report) , another managed-care company with Medicare exposure, offers a useful comparison point for investors watching how government-sponsored health plans balance enrollment growth and medical costs.
Alignment Guidance Supports the Bull Case
Raised 2026 guidance supports the view that scale and margin expansion can continue together. Alignment expects full-year membership of 294,000-299,000 and revenues of roughly $5.160-$5.205 billion.
The adjusted EBITDA outlook of $138-$163 million points to continued operating leverage as the business grows. That matters because the bullish case depends on more than adding members. ALHC also needs automation, clinical management and plan quality to translate growth into better margins.
Surgery Partners (SGRY - Free Report) , a healthcare-services company focused on surgical facilities and ancillary services, provides a broader sector reminder that execution models matter. For Alignment, the key model question is whether its clinical-first platform can keep higher-acuity growth profitable.
ALHC Valuation Sets a Higher Bar
The stock is not an obvious bargain after its advance. Shares were up 24.3% year to date and 79.1% over the trailing 12 months, well ahead of the Zacks Medical sector and the broader S&P 500 over those periods.
ALHC recently traded around 0.9X forward 12-month sales, above its five-year median of 0.7X. Better execution is being recognized, which means the next leg higher may require fresh estimate momentum, further margin proof or a more attractive entry point.
Image Source: Zacks Investment Research
ALHC’s valuation is still below broader market sales multiples, but that alone does not settle the debate. The company is being valued more richly than its own historical median, so investors need confidence that guidance can be met without utilization pressure eroding the earnings path.
Alignment Balance Sheet Adds Flexibility
Liquidity remains a meaningful support to the investment case. First-quarter operating cash flow climbed to $128.7 million from $16.6 million a year earlier, adding evidence that improved earnings are showing up in cash generation.
Alignment ended the quarter with about $726 million in cash, cash equivalents and short-term investments. Management expects 2026 capital expenditures near $40 million, mainly tied to software development and technology investments.
That flexibility gives Alignment room to fund technology, clinical infrastructure and measured expansion without stretching the balance sheet. It also helps absorb near-term variability tied to higher-acuity members, risk-model changes and revenue timing.
Based on short-term price targets offered by 13 analysts, the average price target of $24.92 represents an increase of 1.5% from the last closing price.
Image Source: Zacks Investment Research
What ALHC Ratings Say Now
The bottom line is balanced. ALHC has better profitability, higher guidance, stronger cash flow and a growing member base, but the stock already reflects a good portion of that operational progress.
The stock currently carries a Zacks Rank #3 (Hold), which is consistent with that setup. A Zacks Rank #3 can fit a stock with improving fundamentals but a less obvious near-term entry point after a sizable rally.
Alignment also has a VGM Score of B and a Growth Score of A, which support the long-term operating story. Its Value Score of C and Momentum Score of D are less favorable, suggesting investors may want more valuation support or renewed estimate momentum before treating ALHC as a more compelling buy.
View the Zacks #1 Rank List
Image: Bigstock
Is ALHC Stock Worth Buying After a Big Rally and Higher Forecasts
Key Takeaways
Alignment Healthcare (ALHC - Free Report) has given investors a clearer profitability story, but the stock’s rally has made the buy case less straightforward.
The question now is not whether execution has improved. It has. The harder question is whether the current price still leaves enough room for upside after investors have already rewarded that progress.
ALHC Earnings Momentum Looks Real
First-quarter 2026 results showed that Alignment’s operating model is moving beyond a long-range profitability promise. Revenues rose 33.3% year over year to $1.23 billion, supported by membership expansion and higher per-member revenue.
The company reported earnings of 5 cents per share compared with a loss of 5 cents a year earlier. Adjusted EBITDA increased 87.6% to $37.9 million, while the Medical Benefit Ratio improved to 88.2% from 88.4%, signaling modestly better medical-cost control.
Membership reached about 284,800, up 30.9% year over year. Molina Healthcare (MOH - Free Report) , another managed-care company with Medicare exposure, offers a useful comparison point for investors watching how government-sponsored health plans balance enrollment growth and medical costs.
Alignment Guidance Supports the Bull Case
Raised 2026 guidance supports the view that scale and margin expansion can continue together. Alignment expects full-year membership of 294,000-299,000 and revenues of roughly $5.160-$5.205 billion.
The adjusted EBITDA outlook of $138-$163 million points to continued operating leverage as the business grows. That matters because the bullish case depends on more than adding members. ALHC also needs automation, clinical management and plan quality to translate growth into better margins.
Surgery Partners (SGRY - Free Report) , a healthcare-services company focused on surgical facilities and ancillary services, provides a broader sector reminder that execution models matter. For Alignment, the key model question is whether its clinical-first platform can keep higher-acuity growth profitable.
ALHC Valuation Sets a Higher Bar
The stock is not an obvious bargain after its advance. Shares were up 24.3% year to date and 79.1% over the trailing 12 months, well ahead of the Zacks Medical sector and the broader S&P 500 over those periods.
ALHC recently traded around 0.9X forward 12-month sales, above its five-year median of 0.7X. Better execution is being recognized, which means the next leg higher may require fresh estimate momentum, further margin proof or a more attractive entry point.
Image Source: Zacks Investment Research
ALHC’s valuation is still below broader market sales multiples, but that alone does not settle the debate. The company is being valued more richly than its own historical median, so investors need confidence that guidance can be met without utilization pressure eroding the earnings path.
Alignment Balance Sheet Adds Flexibility
Liquidity remains a meaningful support to the investment case. First-quarter operating cash flow climbed to $128.7 million from $16.6 million a year earlier, adding evidence that improved earnings are showing up in cash generation.
Alignment ended the quarter with about $726 million in cash, cash equivalents and short-term investments. Management expects 2026 capital expenditures near $40 million, mainly tied to software development and technology investments.
That flexibility gives Alignment room to fund technology, clinical infrastructure and measured expansion without stretching the balance sheet. It also helps absorb near-term variability tied to higher-acuity members, risk-model changes and revenue timing.
Based on short-term price targets offered by 13 analysts, the average price target of $24.92 represents an increase of 1.5% from the last closing price.
Image Source: Zacks Investment Research
What ALHC Ratings Say Now
The bottom line is balanced. ALHC has better profitability, higher guidance, stronger cash flow and a growing member base, but the stock already reflects a good portion of that operational progress.
The stock currently carries a Zacks Rank #3 (Hold), which is consistent with that setup. A Zacks Rank #3 can fit a stock with improving fundamentals but a less obvious near-term entry point after a sizable rally.
Alignment also has a VGM Score of B and a Growth Score of A, which support the long-term operating story. Its Value Score of C and Momentum Score of D are less favorable, suggesting investors may want more valuation support or renewed estimate momentum before treating ALHC as a more compelling buy.